Earnings Exceed Expectations but Plunge 11%—Where Did KRYS Go Wrong?

NEXT PICK · Market Insights

Earnings Exceed Expectations but Plunge 11%—Where Did KRYS Go Wrong?

Monday, November 2, 2026

KRYS surged onto the trending list today, not because of a performance collapse; on the contrary: Q3 revenue was $127.3 million, up 30% year-on-year, diluted earnings per share of $2.05, both above market expectations, and it also announced a $400 million buyback.

However, the stock price plunged 10.95% that day, closing at $295.9, with trading volume expanding to 4.4 times the daily average over the past three months.

The company has not announced any "bad news," and the company has not explained the decline, but the same financial report lists two delays: the topline data for the eye project KB803 has been postponed from the originally scheduled fourth quarter this year to the last visit in February next year, and the interim results for the cystic fibrosis project KB407 have also been pushed back to the first half of next year.

A company with a market value of $8.76 billion and a price-to-earnings ratio of 37 times lost about $1.08 billion in a single day. Is this a misjudgment, or has high valuation finally provided a reason to exit?

Latest price $295.9 ▼ -10.95%

Quantity ratio 4.4 times ▲ Compared to the 3-month average daily a surge in volume

Price-to-earnings ratio 37.08 times — Rolling caliber

A gene drug applied to wounds supports a market value of 8.7 billion

Krystal Biotech is a gene drug company that has already passed the threshold of commercialization, with all product revenue coming from a single drug: VYJUVEK, used to treat malnutrition-type epidermolysis bullosa (DEB), a rare genetic disease where skin is so fragile that it blisters and breaks at the slightest friction.

The income curve is quite solid

In the first nine months of this year, revenue was $362.9 million, up 28.7% year-on-year; For the three quarters, revenue was $116.4 million, $119.2 million, and $127.3 million, respectively.

Since listing, cumulative revenue has reached about $1.1 billion, with about $1.2 billion in cash and investments on hand.

This financial report also adds a piece of the long-missing puzzle

In Q3, US revenue was $95.3 million, with overseas revenue of $32 million, accounting for about a quarter of the overseas market. Europe and Japan have already approved it, Germany and Italy have completed pricing negotiations, but the single product remains the same, but the single market is no longer the same. **

But the U.S. base is worth a closer look

$95.3 million is even lower than the $97.8 million global total revenue in the same period last year. In other words, a significant portion of this quarter's high year-on-year growth was contributed by new overseas markets.

The moat is deeper than its breadth; for irreplaceability, we give it 8 points

Its irreplaceability does not come from the production capacity or channels of conventional biologics, but from the HSV-1 vector gene drug platform: mechanistic replenishment of missing proteins, not just wound repair. Once doctors establish screening, dosing, and wound care processes, the clinical cost of changing drugs becomes higher than that of conventional prescription drugs.

Looking at the moat, patents are listed as the basis for competition by the 10-K, but the specific expiration year and coverage are not disclosed item by item, so it can only be considered "potentially strong, details to be verified"; Regulatory thresholds are the most practical; even if latecomers have the same mechanism, they must go through clinical, production, and quality validation, while rare disease patients are few, making recruitment and long-term follow-up slow down.

Switching costs come from processes rather than lock-in

Over 760 reimbursement approvals have been granted nationwide, with more than 80 new prescribing physicians added in the third quarter, and about 80% of American patients are able to self-medicate at home. However, retention and discontinuation rates have not been disclosed, so this stickiness cannot be quantified as permanent lock-in.

Network effects are almost nonexistent; drugs don't become more effective just because more people use them. True positive feedback is just an "evidence network": the more people use it, the richer the real-world data and doctors' experience. Manufacturing and commercialization capabilities are the real thresholds, but capacity, batches, and inventory are also lacking disclosure, so scale advantages cannot be considered complete.

**This is a deep and narrow moat

This explains a 55.9% operating profit margin, yet it cannot block the risks of a single product. ** Does a company that relies on a single drug really deserve the valuation of a platform-based company?

37x or 40x? The caliber battle behind the price-to-earnings ratio

The market terminal shows a price-to-earnings ratio (P/E) of 37.08 times, corresponding to earnings per share of $7.98; But on a quarter-by-quarter basis, diluted earnings per share over the past four quarters are $7.36, which is about 40 times the current price. We prefer to believe the latter because it can be traced back to company disclosures.

Other anchors are also not cheap

The price-to-sales ratio (P/S) is about 19x, the price-to-book ratio (P/B) is 6.10x, the enterprise value multiple (EV/EBITDA) is 33.90x, and the snapshot of free cash flow yield (FCF) is only 1.15%.

The market clearly did not price it as a low-growth pharmaceutical company, but instead paid for growth, product longevity, and pipeline options together.

The only thing that looks cheap is the price-to-earnings growth ratio (PEG) of 0.55, corresponding to 32.59% revenue growth and 64.53% net profit growth. But it's only a supplementary indicator; without historical and peer valuation ranges, it can't overcome pressure by several absolute multiples, and net profit growth itself is affected by the base.

Based on conservative earnings, the current price still has no discount

The report sets the benchmark range with a diluted earnings per share of $6.84 and a P/E ratio of 30 to 40 times for fiscal year 2025, with current prices about 8.0% above the upper boundary and about 44.3% above the lower boundary. Replacing the earnings benchmark with the latest $7.36, the current price is also almost above the upper bound of 40 times, so the margin of safety is still not there.

In terms of scenario, earnings per share at $6.84 with only 28 times are a pessimistic scenario; A neutral version of $7.20 to $7.60 with 30 to 35 times is a neutral version.

$7.80 with 35 times is more optimistic; $8.40 with 40 times is the high-scenario, requiring revenue growth close to 30% and operating profit margin to around 55%.

Cross-verification of price-to-sales ratios points to the same conclusion

Assuming 2026 scenario revenue of $475 million to $520 million, or 14 to 17 times, with an implied market value of $6.65 billion to $8.84 billion, the current price would need to be close to 17 times to make sense, leaving little room for error.

Cash flow is real, but it can't be bought cheaply

Free cash flow (FCF) for fiscal year 2025 is $200.9 million, up 62.8% from $123.4 million the previous year, with a margin of about 51.6%, equivalent to 98.1% of net profit of $204.8 million.

FCF in the first quarter of this year was $80.4 million, accounting for 143.8% of net profit for the quarter, clearly indicating the company is self-sustaining.

The $1.2 billion in cash and investments on hand account for about 14% of the market value, enough to simultaneously support pipelines, overseas expansion, and $400 million in buybacks. However, FCF for Q2 and Q3 did not enter the current recognized data, so the high conversion rate in Q1 cannot be directly extrapopulated; For fiscal year 2025, the static yield is only about 2.3%.

So, has today's drop been priced in? Our judgment is: the emotional shock from the delay has largely been reflected in the stock price, but only part of the valuation pressure has been released; Positive factors like beating expectations and buybacks have also not been priced in by the market. The next step is to rely on data and earnings, not on multiples for recovery.

They've broken through, but are still far from mature

KRYS's most fitting label is "breakthrough period": quarterly revenue of $127.3 million, three consecutive quarters of quarter-on-quarter growth, operating profits of $53.7 million, $58.4 million, and $71.1 million respectively, with a Q3 profit margin of 55.9%. The core question has shifted from "can we sell it" to "whether growth, overseas, and pipeline relays can be delivered?"

It is said to be immature because revenue is still concentrated in one drug: KB407 and KB408 are in Phase I, KB301 in Phase II, and KB707 in Phase I/II, all unvalidated, while the market still rates them as high growth.

Today's close was about 12.3% below the 50-day moving average and about 4.1% below the 200-day moving average, with the 50-day moving average still above the 200-day line. The market has not ruled out a breakout but is no longer willing to pay a premium for it.

The opponent has already entered the arena, but hasn't truly hurt it yet

The most easily underestimated is Abeona's ZEVASKYN (i.e., EB-101): it has been commercialized and follows the route of individually cultivating genetically modified cell slices for patients.

Net revenue in Q2 this year was $11.4 million, with 12 treatments completed since listing, including some substandard batches, far from VYJUVEK's single-quarter $127.3 million.

Its threat isn't in today's share, but in pricing and budgeting: once a surge in volume, payers and doctors have another option. Abeona still lost $2020 million in Q2, with limited confidence in short-term price wars, but it's no longer a pipeline that only counts when it reboots.

Castle Creek's CCHB-101 (dabocemagene autoficel) also targets gene functional supplementation and is a worthy follow-up competitor to follow, with no new clinical developments found through public channels.

Its value still depends on later clinical, regulatory, and manufacturing validation; better efficacy, convenience, or payment terms may weaken KRYS's first-mover advantage.

Chiesi's FILSUVEZ is another path: a topical gel approved by the FDA in December 2023 for wound management rather than gene supplementation, thanks to its simple process and complex production without gene therapy.

Wound management programs like Integra and long-term standard care systems are competing for patient budgets, physician attention, and treatment pathways.

First-mover advantage is like grabbing the top of the mountain, but the top doesn't mean the whole mountain belongs to you. Due to the lack of verifiable data on patient shares, net prices, and prescription volumes among providers, any assertions about "pricing power" should be exercised with restraint.

The ceiling can't be calculated, only the runway

There is a lack of reliable data on total patient numbers, diagnosis rates, net prices, and reimbursement populations across regions, so it is not advisable to rigidly calculate amounts for TAM, SAM, and SOM.

Observable TAMs include existing indications, geographic expansion, substitution of traditional wound management, and the space for platform extensions to KB803, KB801, KB407, KB111, KB707, KB408, and KB301, but early projects cannot be merged.

SAM is no longer limited to the US: overseas single-quarter $32 million, over 20 centers in Germany starting medication, Italy plans to launch early next year, Spain pricing expected to be released within the year, and France no earlier than 2027.

SOM directly looks at revenue: $389.1 million in fiscal year 2025, with an annualized figure of about $509.2 million in Q3.

Three-Year Scenario (Non-Company Guidelines)

In 2026, it is expected to be between $475 million and $520 million, with a median of about $498 million, corresponding to $112 million to $157 million in Q4.

570 million to 650 million in 2027, with a median of about 610 million; 650 million to 780 million in 2028, with a median of about 715 million. These only reflect existing products and are not included in the first and second phase pipelines.

After exceeding expectations, what cards do the bulls still hold?

Bulls don't bet on valuation expansion; they bet on revenue, profit margins, and pipeline fulfillment simultaneously, allowing profits to absorb multiples:

▲ Bull Case

Bears do not deny the company, only question the price

Bears do not deny the quality of the companies; what they want to say is that current prices already require high growth, high profit margins, high cash conversion, and low clinical failure rates all at once:

▼ Bear Case

In the next six months, the numbers will be more important than the financial report

The next step for the stock price will most likely depend on whether this timeline can be delivered on time, and this time it has already missed a round:

•	KB111 interim results: By the end of this year, only 5 patients had directional effects, biased toward platform validation
•	Japan's prescription frequency was relaxed from biweekly to monthly: November to December, which is favorable for overseas a surge in volume
•	Spain pricing decision: within this year; Italian listing: early next year, benefiting overseas revenue
•	KB803's final visit: In February next year, the top line will be announced afterwards. Major events, success or failure, will clearly affect the stock price
•	Interim results for KB407 communicate with the FDA: The impact direction in the first half of next year depends on the data
•	Whether revenue can maintain around 30% growth and profit margins above 50% over the next 2 to 4 quarters determines whether valuations can be absorbed
•	KB801 top-line enrollment, KB408 mid-term, KB304 initiation phase two, KB707 about 70 cases (mid-next year): gradually implemented within 2027, moderate impact

After a 40% increase, the market began to nitpick

Over the past 12 months, KRYS has risen 43.1%, rising from $184.02 to $382.54 over the 52-week range.

What supports this market is its performance

Fiscal year 2025 revenue will increase from $290.5 million to $389.1 million, and operating profit will increase from $65.7 million to $161.3 million, a growth of 145.5%.

Net profit increased from $89.2 million to $204.8 million, an increase of 129.6%.

The turning point will come in the second half of the year

On July 29, the closing price was still at $363.28, but the Q2 earnings per share in early August exceeded expectations but revenue slightly fell short of expectations, causing the stock price to gap down.

Today was another unexpectedly plunge, with the current price dropping about 22.6% from its 52-week high. The market's benchmark for this company is clearly no longer "whether it exceeds expectations."

Looking back, judgments like "this is not a pure concept stock," "high growth without sacrificing profits," and "cash flow supporting reinvestment" have all been validated.

It is necessary to correct that growth rates of 28.7% to 30.2% cannot be considered permanently stable, and early pipelines cannot be valued according to mature product standards. Currently, the company is in the stage of valuation digestion and earnings verification; whether this will be repriced or trend reversal depends on subsequent data.

⚠️ Risk Notice • Revenue comes almost entirely from VYJUVEK, and security, manufacturing, or payment events directly impact overall performance • Current prices are above a reasonable range for conservative earnings benchmarks, so valuation compression risks increase when growth slows • Pipeline readings have already been delayed, and results such as KB803 falling short of expectations or being delayed again will hurt valuations • The timing of regulatory approvals and overseas pricing is uncertain; France will not be before 2027 • Limited disclosure of U.S. revenue growth, and ZEVASKYN's a surge in volume may lead to pricing and budget competition

🟡 Neutral The earnings report passed but the reading was delayed, and the roughly 40x valuation still needs to be digested by profits

💬 Discussion The current price is not cheap, so wait for the data to increase the bet.

Data source

•	Source: NextPick real-time snapshots, company Q3 earnings and earnings calls, SEC announcements, and mainstream financial media; Competitor status The original research report has been updated according to the latest public information.